Drugs in the Pipeline
Amgen and Allergan announced that their biosimilar candidate ABP 215 met its primary and secondary endpoints in a Phase 3 study evaluating its efficacy and safety compared with Avastin (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.
Drugs in the Pipeline
Eli Lilly and Company announced today that the Phase 3 POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of Alimta (pemetrexed for injection) with bevacizumab (Avastin; Genentech) and carboplatin induction followed by Alimta plus bevacizumab maintenance-the Alimta arm-compared to the combination of paclitaxel (Taxol; Bristol-Myers Squibb) with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
Drugs in the Pipeline
Carboplatin plus first-line combination pemetrexed and bevacizumab therapy exhibits efficacy among elderly patients diagnosed with nonsquamous NSCLC, found data presented at ASCO 2013.
Drugs in the Pipeline
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Drugs in the Pipeline
Mirvetuximuab soravtansine uses a humanized FRα-binding antibody to target antibody-drug conjugates specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.
Drugs in the Pipeline
Regeneron announced results from an effectiveness study sponsored by the National Institutes of Health (NIH) in patients with diabetic macular edema (DME) treated with Eylea (aflibercept) Injection compared to Avastin (bevacizumab; Genentech) and Lucentis (ranibizumab; Genentech).
Drugs in the Pipeline
Amgen announced the results from a Phase 3 study, Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) which evaluated Neulasta (pegfilgrastim) for the first-line treatment of locally-advanced or metastatic colorectal cancer.
Drugs in the Pipeline
The FDA has accepted Genentech's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer.
Drugs in the Pipeline
Amgen announced new data from its PEAK and PRIME studies that support Vectibix (panitumumab), in combination with FOLFOX, as first-line therapy in patients with wild-type RAS metastatic colorectal cancer (mCRC)
